MK-677, is a orally bio-active, selective agonist of the ghrelin receptor. Research shows that MK-677 increases the natural secretion of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), but does not affect cortisol levels. It is being researched as a possible treatment for GH deficiency, muscle and bone wasting, appetite stimulation and Alzheimer's disease. MK-677 research in mice, appeared to prevent the onset of AD, even in genetically predisposed mice, as long as it was started before significant amyloid beta accumulation. MK-677 research has also shown exceptionally promising benefits in improving sleep quality.

Tesamorelin’s growing body of evidence highlights its significance not only for HIV-associated lipodystrophy but for broader metabolic research. Its targeted effects, safety profile, and hormonal precision make it a cornerstone peptide in modern endocrinology and metabolic science.